A week-long lab study found tadalafil kept mouse muscle starter cells alive longer while slowing their final step into mature muscle fibers.
Story Snapshot
- Italian scientists tested tadalafil on mouse skeletal muscle cells for seven days.
- The drug increased growth and survival of early muscle cells, with less cell death.
- The same treatment delayed the cells’ maturation into full muscle fibers.
- Human muscle blood-flow studies with similar drugs show mixed but plausible effects.
What the new study actually found in the lab
Researchers exposed C2C12 mouse muscle cells to tadalafil at one micromolar strength for up to seven days. They measured more cell proliferation and higher survival across time points, with fewer dying cells compared to untreated controls. These early cells, often called muscle precursor or satellite-like cells, drive repair after injury. The team also tracked markers of myogenesis. They reported a slower push into the final, fused muscle-fiber stage under tadalafil exposure across the study window.
The authors framed this as a trade-off. Keeping a larger pool of starter cells alive could help repair, but delayed maturation may hold back short-term muscle fiber formation. That tension matters for older adults who want stronger, more resilient muscle. A bigger bench of healthy prospects sounds good, yet points are scored only when prospects become starters. Time, dose, and context likely decide whether this delay helps long-term rebuild or simply slows progress.
Why this fits a broader biological story
Tadalafil blocks an enzyme tied to the cyclic guanosine monophosphate signal, which relaxes blood vessels and can change cell behavior. Work in people shows that enhancing this pathway can raise blood flow and oxygen delivery to working muscle in older men, though not in the young. That human signal supports plausibility. More oxygen and better perfusion can aid repair. Still, not every vascular gain turns into strength, speed, or endurance. Mechanism-level wins often shrink when they meet real-life complexity.
Prior laboratory and animal research with drugs in this class has hinted at tissue benefits outside sexual health, from bone density shifts to muscle metabolism changes. Those threads align with the current mouse-cell findings and suggest a shared pathway could touch several aging tissues. The pattern is consistent: a clear, measurable biological nudge shows up first in controlled systems, then researchers test if it matters to how people feel, move, and live.
What this does and does not mean for men over 50
The lab result shows tadalafil can keep mouse muscle precursor cells alive longer and delay their final maturation over one week. It does not show that tadalafil builds muscle in humans or improves daily function. Coverage that jumps from petri-dish gains to gym-floor results skips necessary steps. Responsible reporting should keep that chain intact. The sensible takeaway is curiosity with restraint: the target is worthy, the mechanism is real, and translation to people is the next test.
UNEXPECTED UPSIDE: Researchers in Italy discovered that tadalafil — the active ingredient in the erectile dysfunction drug Cialis — boosted the growth and survival of muscle precursor cells in a lab study using mouse skeletal muscle cells.
The seven-day experiment, published in… pic.twitter.com/oetqIkfY0S
— Fox News Health (@foxnewshealth) October 13, 2026
Common sense and conservative values favor proof before policy or practice. Doctors should not change care on the basis of a single mouse-cell study. Patients should not self-medicate for muscle with a drug meant for erectile dysfunction. Strong evidence in humans, with measured outcomes like strength, walking speed, and fall risk, must come first. If future trials confirm benefit at safe doses, then a cheap, known drug could help older adults keep muscle — a win for health and wallets.
What to watch next
Researchers should run dose-ranging studies in animals and small pilot trials in people. The key outcomes should track both sides of the trade-off: size of the precursor pool and the speed and quality of final muscle fiber repair. Trials should include older adults after muscle strain, surgery, or illness, with clear measures of strength, function, and recovery time. If the delay in maturation proves brief and helpful, the larger pool could pay off. If not, strategy must shift.
Sources:
pmc.ncbi.nlm.nih.gov, link.springer.com, ncbi.nlm.nih.gov
